Literature DB >> 6609824

Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity.

F Y Liew, S M Russell, G Appleyard, C M Brand, J Beale.   

Abstract

Mice previously infected with an aerosol of A/Rec 31 influenza virus were strongly protected against an aerosol challenge with A/Vic influenza as judged by lung virus titers recovered 2 days after the challenge infection. Such complete homotypic immunity was not achieved by priming with live Rec 31 virus injected i.v. or UV-inactivated Rec 31 virus administered s.c. together with Al(OH)3 and saponin. The reason for the superior protective effect of the natural infection was investigated. The protection induced by respiratory infection with Rec 31 virus was specific for influenza A viruses. It was not correlated with specific serum hemagglutination inhibition antibody titer or cross-reactive cytotoxic T (Tc) cell reactivity. Moreover, the transfer of splenic and lymphoid T cell populations with strong secondary Tc activity did not significantly reduce lung virus titers in recipient mice 3 days after infection. The protection however occurred in parallel with the presence of cross-reactive IgA antibody in the lung washings. It thus appears that local secretory IgA plays a causal role in the prevention of cross-infection by influenza A virus. Serum antibody and Tc cells, on the other hand, may be crucial for recovery from such infection. All mice primed with live Rec 31 virus, administered i.v. or by aerosol and expressing equally high levels of Tc reactivity, survived a lethal challenge with A/PR8 virus. The same challenge, however, killed half of the mice immunized s.c. with inactivated Rec 31 virus which induced only a low level of Tc reactivity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6609824     DOI: 10.1002/eji.1830140414

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  88 in total

1.  Intracellular neutralization of virus by immunoglobulin A antibodies.

Authors:  M B Mazanec; C S Kaetzel; M E Lamm; D Fletcher; J G Nedrud
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

Review 2.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

3.  Epitope specific T-cell responses against influenza A in a healthy population.

Authors:  Miloje Savic; Jennifer L Dembinski; Yohan Kim; Gro Tunheim; Rebecca J Cox; Fredrik Oftung; Bjoern Peters; Siri Mjaaland
Journal:  Immunology       Date:  2015-12-08       Impact factor: 7.397

4.  The IgA and subclass IgG responses and protection in mice immunised with influenza antigens administered as ISCOMS, with FCA, ALH or as infectious virus.

Authors:  E T Ben Ahmeida; R Jennings; M Erturk; C W Potter
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

Review 5.  New aspects of vaccine development.

Authors:  F Y Liew
Journal:  Clin Exp Immunol       Date:  1985-11       Impact factor: 4.330

6.  Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus.

Authors:  Joshua M DiNapoli; Lijuan Yang; Amorsolo Suguitan; Subbiah Elankumaran; David W Dorward; Brian R Murphy; Siba K Samal; Peter L Collins; Alexander Bukreyev
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

7.  Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus.

Authors:  T Muster; B Ferko; A Klima; M Purtscher; A Trkola; P Schulz; A Grassauer; O G Engelhardt; A García-Sástre; P Palese
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Immunity to vaginal HSV-2 infection in immunoglobulin A knockout mice.

Authors:  M B Parr; G R Harriman; E L Parr
Journal:  Immunology       Date:  1998-10       Impact factor: 7.397

9.  Sublingual administration of bacteria-expressed influenza virus hemagglutinin 1 (HA1) induces protection against infection with 2009 pandemic H1N1 influenza virus.

Authors:  Byoung-Shik Shim; Jung-Ah Choi; Ho-Hyun Song; Sung-Moo Park; In Su Cheon; Ji-Eun Jang; Sun Je Woo; Chung Hwan Cho; Min-Suk Song; Hyemi Kim; Kyung Joo Song; Jae Myun Lee; Suhng Wook Kim; Dae Sub Song; Young Ki Choi; Jae-Ouk Kim; Huan Huu Nguyen; Dong Wook Kim; Young Yil Bahk; Cheol-Heui Yun; Man Ki Song
Journal:  J Microbiol       Date:  2013-03-02       Impact factor: 3.422

10.  Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans.

Authors:  Robert B Couch; Robert L Atmar; Thomas R Cate; John M Quarles; Wendy A Keitel; Nancy H Arden; Janet Wells; Diane Niño; Philip R Wyde
Journal:  Vaccine       Date:  2009-07-14       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.